Literature DB >> 17570538

Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine.

Min Zhang1, Michael E Ballard, Liliane V Unger, Andreas Haupt, Gerhard Gross, Michael W Decker, Karla U Drescher, Lynne E Rueter.   

Abstract

Rats treated with apomorphine and amphetamine display sensorimotor gating impairments, as measured by prepulse inhibition (PPI), and these impairments can be reversed by antipsychotic treatment. However, it remains unknown whether the dopamine (DA) D(3) receptor plays a role in mediating these effects on PPI, as none of these DA agonists or antipsychotics are exclusively selective at either D(2) or D(3) receptors. To address this question, the current study was designed to investigate whether antipsychotic drugs and selective D(3) antagonists could block the PPI-disruptive effects of PD 128907 (a preferential D(3) agonist) and apomorphine. We found that the effect of PD 128907 on PPI in rats could be antagonized by risperidone, clozapine, and the selective D(3) antagonists SB 277011 and A-691990, but not by raclopride or haloperidol, while the apomorphine-induced PPI deficit could be reversed by risperidone, clozapine and haloperidol, but not by SB 2770111 and A-691990. These results suggest that the D(3) receptor does not mediate apomorphine-induced disruption of PPI in rats, however, given the findings that PD 128907 elicited a PPI-disruptive effect that was blocked by selective D(3) antagonists, a role of D(3) receptor in mediating PPI in rats cannot be ruled out. The possible mechanisms of D(3) receptor involvement in PPI are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570538     DOI: 10.1016/j.bbr.2007.04.021

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  12 in total

1.  The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats.

Authors:  Martin Weber; Wei-Li Chang; Michelle R Breier; Alex Yang; Mark J Millan; Neal R Swerdlow
Journal:  Eur Neuropsychopharmacol       Date:  2010-03-25       Impact factor: 4.600

Review 2.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

3.  Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44.

Authors:  Martin Weber; Wei-Li Chang; John P Durbin; Paula E Park; Robert R Luedtke; Robert H Mach; Neal R Swerdlow
Journal:  Pharmacol Biochem Behav       Date:  2009-05-06       Impact factor: 3.533

4.  Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats.

Authors:  Wei-li Chang; Michelle R Breier; Alex Yang; Neal R Swerdlow
Journal:  Pharmacol Biochem Behav       Date:  2011-06-12       Impact factor: 3.533

5.  Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats.

Authors:  Wei-Li Chang; Martin Weber; Michelle R Breier; Richard L Saint Marie; Samantha R Hines; Neal R Swerdlow
Journal:  Brain Res       Date:  2011-12-13       Impact factor: 3.252

6.  Stimulation of Dopamine D3 Receptor Attenuates Renal Ischemia-Reperfusion Injury via Increased Linkage With Gα12.

Authors:  Zhen Wang; Weiwei Guan; Yu Han; Hongmei Ren; Xiaofeng Tang; Hui Zhang; Yukai Liu; Jinjuan Fu; Duofen He; Laureano D Asico; Pedro A Jose; Lin Zhou; Liyong Chen; Chunyu Zeng
Journal:  Transplantation       Date:  2015-11       Impact factor: 4.939

Review 7.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

8.  Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia.

Authors:  Xue Sun; Hong-yan Gou; Fei Li; Guan-yi Lu; Rui Song; Ri-fang Yang; Ning Wu; Rui-bin Su; Bin Cong; Jin Li
Journal:  Acta Pharmacol Sin       Date:  2016-01-18       Impact factor: 6.150

9.  Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine.

Authors:  M Weber; M Breier; D Ko; N Thangaraj; D E Marzan; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2008-12-09       Impact factor: 4.530

10.  Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation.

Authors:  Martin Weber; Wei-li Chang; Michelle Breier; David Ko; Neal R Swerdlow
Journal:  Behav Pharmacol       Date:  2008-12       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.